English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met.
- ✅ Price trend passed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2023 → 2024: -16.97%
Price change 2024 → 2025: 31.56%
Price change 2025 → 2026: 58.28%
Price change 2026 (year to date): 56.43%
Financial growth
Revenue CAGR (7 years): N/A
Earnings CAGR (7 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.00
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -6.82
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 16.11% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="SGMT" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Sagimet Biosciences Inc. | – | 0.00 | – | 🔒 |
| Eurobio Scientific S.A. | 36.8 | 0.09 | +22.1 % | – |
| Boiron S.A. | 12.4 | 0.08 | −0.2 % | – |
| LNA Santé S.A. | 9.7 | 2.75 | +10.4 % | – |
| Valerio Therapeutics S.A. | – | 3.67 | −13.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by Sagimet Biosciences Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 56.7 m | 32.3 m | 94.9 m | 151 m | 113 m |
| Total Debt | 348,000 | 211,000 | 65,000 | 78,000 | 78,000 |
| Net Debt | -56.4 m | 53,000 | -75.1 m | -75.8 m | -34.9 m |
| Equity | -158 m | -187 m | 91.1 m | 156 m | 111 m |
| Total assets | 59.0 m | 33.0 m | 96.7 m | 160 m | 116 m |
| Operating cash flow | -21.7 m | -24.5 m | -23.8 m | -42.4 m | -45.6 m |
| Investments (capex) | 0 | 0 | 0 | 0 | 0 |
| Free cash-flow | -21.7 m | -24.5 m | -23.8 m | -42.4 m | -45.6 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Sagimet Biosciences Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Sagimet Biosciences Inc. | 323 m | n/a | 0.0 % |
| Arcturus Therapeutics Holdings Inc. ARCT | 314 m | n/a | -97.9 % |
| Humacyte, Inc. HUMA | 114 m | n/a | -2,003.6 % |
| Assembly Biosciences, Inc. ASMB | 410 m | 19.7 | -8.5 % |
| Zura Bio Limited ZURA | 389 m | n/a | 0.0 % |
| Voyager Therapeutics, Inc. VYGR | 106 m | n/a | -296.5 % |
| Entrada Therapeutics, Inc. TRDA | 177 m | n/a | -565.5 % |
| Foghorn Therapeutics Inc. FHTX | 124 m | n/a | -240.3 % |
| Immuneering Corporation IMRX | 243 m | n/a | 0.0 % |
| Sector median (Nasdaq) | 20.5 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Sagimet Biosciences Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Average target over the last 3 months: 20.00 USD (4 targets).
Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Sagimet Biosciences Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 12/11/2026. Expected EPS: -0.25.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Sagimet Biosciences Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| BlackRock | 6.6 m | 50.8 m | 0.0 % | +722.0 % | 2026Q2 |
| State Street | 4.0 m | 30.8 m | 0.0 % | +2,998.3 % | 2026Q2 |
| Geode Capital Management | 1.4 m | 11.2 m | 0.0 % | +366.5 % | 2026Q2 |
| Vanguard Group | 1.3 m | 7.5 m | 0.0 % | +4.7 % | 2025Q4 |
| Millennium Management | 937,025 | 7.2 m | 0.0 % | +8.7 % | 2026Q2 |
| Goldman Sachs | 759,086 | 5.9 m | 0.0 % | +348.5 % | 2026Q2 |
| Northern Trust | 468,385 | 3.6 m | 0.0 % | +743.8 % | 2026Q2 |
| Renaissance Technologies | 346,927 | 2.7 m | 0.0 % | -44.5 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 14/08/2026 | Kemble George | sale | 3.6 m USD |
| 11/08/2026 | Kemble George | sale | 201,147 USD |
| 20/07/2026 | Happel David | sale | 497,068 USD |
| 20/07/2026 | Rozek Elizabeth | sale | 81,832 USD |
| 20/07/2026 | Kemble George | sale | 140,529 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Sagimet Biosciences Inc.
What is the Sagimet Biosciences Inc. share price?
Latest recorded price: 9.85 USD on 06/11/2026, for a market cap of 321 m USD.
When does Sagimet Biosciences Inc. report its next earnings?
The next release is expected on 12/11/2026. EPS expected by analysts: -0.25.
What do analysts say about Sagimet Biosciences Inc.?
Out of 9 analysts: 8 buy or strong buy, 1 hold, 0 sell or strong sell. Average price target: 20.00 USD, i.e. +101.6 % from the share price.
Is Sagimet Biosciences Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US7867001049).
How many employees does Sagimet Biosciences Inc. have?
14 full-time employees according to the latest published profile.
Who runs Sagimet Biosciences Inc.?
David A. Happel is the company's chief executive.
Which large funds own Sagimet Biosciences Inc.?
As of 2026Q2, among the large funds tracked: BlackRock, State Street, Geode Capital Management, Vanguard Group, Millennium Management.